Expertise in
17
conditions

Dr. Michael B. Denenberg

Rock Hill, SC
Expertise in
17
conditions
Specialties:Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
OverviewInsuranceLocationsClinical Research

Overview

Michael Denenberg is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Rock Hill, South Carolina. Dr. Denenberg is highly rated in 17 conditions, according to our data. His top areas of expertise are Emphysema, Bullae, Pleural Effusion, Pleurisy, and Advanced Bronchoscopy. Dr. Denenberg is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Sleep Medicine
Licenses
Sleep Medicine in SC
Hospital Affiliations
Piedmont Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

370 Herlong Ave S, Suite 200, Rock Hill, SC 29732
803-980-5864

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of of Tiotropium Bromide Inhalation Solution in Subjects With COPD
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of of Tiotropium Bromide Inhalation Solution in Subjects With COPD
Enrollment Status: Completed
Publish Date: May 10, 2021
Intervention Type: Drug
Study Drug: Tiotropium Bromide Inhalation Solution
Study Phase: Phase 2
View 5 Less Clinical Trials

3 Total Publications

Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
Journal: Respiratory medicine
Published: July 23, 2017
Similar Doctors
Expertise in
20
conditions
Dr. Ramarao Suresh
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
20
conditions
Dr. Ramarao Suresh
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Carolinas Physicians Network Inc

10628 Park Rd, 
Charlotte, NC 
 (17.8 mi)
704-667-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ramarao Suresh is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Charlotte, North Carolina. Dr. Suresh is highly rated in 20 conditions, according to our data. His top areas of expertise are Lung Metastases, Bronchiolitis Obliterans, Industrial Bronchitis, Emphysema, and Gastrostomy. Dr. Suresh is currently accepting new patients.

Expertise in
17
conditions
Dr. Rico V. Mendoza
Intensive Care Medicine | Pulmonary Medicine | Sleep Medicine
Expertise in
17
conditions
Dr. Rico V. Mendoza
Intensive Care Medicine | Pulmonary Medicine | Sleep Medicine
2030 N Church St Pl, 
Spartanburg, SC 
 (48.8 mi)
864-582-5858
Languages Spoken:
English, Castilian, Filipino, Spanish
See accepted insurances
Accepting New Patients

Rico Mendoza is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Mendoza is highly rated in 17 conditions, according to our data. His top areas of expertise are Bronchiolitis Obliterans, Industrial Bronchitis, Asthma, Advanced Bronchoscopy, and Gastrostomy. Dr. Mendoza is currently accepting new patients.

Expertise in
22
conditions
Dr. Grigor A. Badalyan
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
22
conditions
Dr. Grigor A. Badalyan
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Carolinas Medical Center

1350 S Kings Dr, 
Charlotte, NC 
 (20.8 mi)
704-355-7328
Languages Spoken:
English, Arabic, Armenian, Russian
See accepted insurances
Accepting New Patients

Grigor Badalyan is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Charlotte, North Carolina. Dr. Badalyan is highly rated in 22 conditions, according to our data. His top areas of expertise are Emphysema, Bullae, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Gastrostomy. Dr. Badalyan is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile